Review article

Future directions in managing aniridia-associated keratopathy

Ariane J.H. van Velthoven\textsuperscript{a,b}, Tor P. Utheim, M.D. Dr.\textsuperscript{c,d}, Maria Notara, Dr.\textsuperscript{e}, Dominique Bremond-Gignac, M.D. Dr.\textsuperscript{f,g}, Francisco C. Figueiredo, M.D. Dr.\textsuperscript{h,i}, Heli Skottman, Dr.\textsuperscript{j}, Daniel Aberdam, Dr.\textsuperscript{g}, Julie T. Daniels, Dr.\textsuperscript{k}, Giulio Ferrari, M.D. Dr.\textsuperscript{l}, Christina Grupcheva, M.D. Dr.\textsuperscript{m}, Carina Koppen, M.D. Dr.\textsuperscript{n}, Mohit Parekh, Dr.\textsuperscript{g}, Thomas Ritter, Dr.\textsuperscript{p}, Vito Romano, Dr.\textsuperscript{q}, Stefano Ferrari, Dr.\textsuperscript{r,s,1}, Claus Cursiefen, M.D. Dr.\textsuperscript{e,s,1}, Neil Lagali, Dr.\textsuperscript{t,1}, Vanessa L.S. LaPointe, Dr.\textsuperscript{a,1}, Mor M. Dickman, M.D. Dr.\textsuperscript{a,b,1}

\textsuperscript{a}MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, the Netherlands
\textsuperscript{b}University Eye Clinic Maastricht, Maastricht University Medical Center+, Maastricht, the Netherlands
\textsuperscript{c}Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
\textsuperscript{d}Department of Ophthalmology, Oslo University Hospital, Oslo, Norway
\textsuperscript{e}Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
\textsuperscript{f}Ophthalmology Department, University Hospital Necker-Enfants Malades, APHP, Paris Cité University, Paris, France
\textsuperscript{g}Centre de Recherche des Cordeliers, Sorbonne Paris Cité University, Paris, France
\textsuperscript{h}Department of Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
\textsuperscript{i}Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK
\textsuperscript{j}Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
\textsuperscript{k}UCL Institute of Ophthalmology, London, UK
\textsuperscript{l}Cornea and Ocular Surface Unit, Eye Repair Lab, San Raffaele Hospital, Milan, Italy
\textsuperscript{m}Department of Ophthalmology and Visual Sciences, Medical University of Varna, Varna, Bulgaria
\textsuperscript{n}Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium
\textsuperscript{o}Schepens Eye Research Institute, Harvard Medical School, Boston, MA, USA
\textsuperscript{p}Regenerative Medicine Institute, University of Galway, Galway, Ireland
\textsuperscript{q}Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Ophthalmology Clinic, University of Brescia, Brescia, Italy
\textsuperscript{r}Fondazione Banca degli Occhi del Veneto, Venice, Italy
\textsuperscript{s}Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
\textsuperscript{1}Contributed equally as last authors.

\textsuperscript{*} Corresponding author: Stefano Ferrari, Fondazione Banca degli Occhi del Veneto, Via Paccagnella 11, Venice, Italy.
E-mail address: stefano.ferrari@fbov.it (S. Ferrari).

0039-6257/© 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1016/j.survophthal.2023.04.003
Abstract

Congenital aniridia is a panocular disorder that is typically characterized by iris hypoplasia and aniridia-associated keratopathy (AAK). AAK results in the progressive loss of corneal transparency and thereby loss of vision. Currently, there is no approved therapy to delay or prevent its progression, and clinical management is challenging because of phenotypic variability and high risk of complications after interventions; however, new insights into the molecular pathogenesis of AAK may help improve its management. Here, we review the current understanding about the pathogenesis and management of AAK. We highlight the biological mechanisms involved in AAK development with the aim to develop future treatment options, including surgical, pharmacological, cell therapies, and gene therapies.

© 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Congenital aniridia is a rare disorder, with a prevalence ranging from 1:40,000 to 1:100,000. Aniridia is a term of Greek origin meaning “without iris,” and the absence of iris structures has long been the defining phenotypic characteristic of this disease. In addition to numerous ocular abnormalities, congenital aniridia also affects various other organs, including the brain, gut, pancreas, and olfactory and auditory systems. Other conditions have also been linked to aniridia, such as obesity and narcolepsy. Due to the diverse systemic manifestations, the term aniridia has been widened to aniridia syndrome. Ocular manifestations

![Fig. 1 – Ocular manifestations of the aniridia syndrome.](image-url)
include affected structures of the iris, optic nerve, trabecular meshwork, Schlemm canal, and the lacrimal and meibomian glands, and subsequent ocular complications include nystagmus, dry eye disease, corneal opacification (keratopathy), glaucoma, and cataract.

Foveal and iris hypoplasia, as well as aniridia-associated keratopathy (AAK), are the most common phenotypic anomalies of congenital aniridia, which are present in 80–100% of the cases. Due to the ocular abnormalities, the visual prognosis for aniridia is generally poor, with a best visual acuity of typically 20/100–20/200, even with access to state-of-the-art ophthalmic interventions. As AAK is the leading cause of vision impairment in congenital aniridia, a better understanding and management of this condition would significantly enhance the visual acuity of aniridia patients. To enhance the clinical management of AAK, we present a critical review of the current status of clinical and experimental efforts towards AAK treatment. In this review, we describe the underlying pathology and various strategies for managing AAK. In addition to providing an overview of the present state of affairs, we identify future perspectives and open issues to enhance treatment.

2. Clinical features of AAK

AAK is a progressive opacification of the cornea. It is one of the most sight-limiting and painful manifestations of congenital aniridia and, if not treated, will lead to blindness over time. AAK typically starts in the first decade of life and progresses in early adulthood. Its progression follows a characteristic pattern similar to limbal stem cell deficiency (LSCD) and can be classified using a grading scheme (Fig. 2). In a healthy cornea the limbal border is intact and well-defined (grade 0). At the earliest stage of AAK, vessels start to breach the limbal border (grade 1), followed by inward radial invasion of abnormal translucent epithelium (grade 2) that reaches the central visual axis (grade 3), and eventually develops into a thickened, uneven corneal surface with white opacities (grade 4). The rate of progression is associated to the specific PAX6 mutation.

Other clinical features are increased stromal thickness and reduced corneal touch sensitivity. The epithelium of the central cornea exhibits abnormal morphology even in the earliest stages of keratopathy where the cornea appears clinically normal. In vivo confocal microscopy in patients with aniridia has revealed multiple abnormalities including reduced corneal nerve density, invasion of inflammatory cells, opacification of the anterior stroma, goblet cell hyperplasia, and loss of basal epithelial cells. Moreover, an abnormal tear film composition and meibomian gland dysfunction are related to the development of dry eye disease in aniridia.

Variability in the clinical expression of AAK has been widely reported; however, the true biological and genetic variability must be distinguished from the variability resulting from differing examination techniques and methods of reporting. Because the earliest stages of AAK are often overlooked, a broader definition of AAK supported by advanced testing and imaging techniques would aid in its documentation and grading, thereby supporting the description of the true biological variation. Importantly, AAK typically co-occurs with a range of other abnormalities associated with congenital aniridia. These systemic and ocular abnormalities significantly impact the treatment and prognosis of AAK. Therefore, it is essential to consider the combined abnormalities when managing AAK. For instance, glaucoma develops in more than 50% of aniridia patients. Additionally, patients who require corneal surgery are at higher risk of developing glaucoma than those who do not.
3. Fundamental basis of AAK pathogenesis

The majority (90%) of aniridia cases are caused by a haploinsufficiency of the PAX6 gene located on chromosome 11p13, which can occur sporadically or can be inherited in an autosomal dominant manner. Over 500 unique heterozygous loss-of-function mutations of PAX6 have been reported to result in aniridia. In addition, mutations in the noncoding regulatory and intronic regions of PAX6 have also been identified in aniridia, including the neighboring genes TRIM44 and ELP4. The genetic heterogeneity of aniridia may partially explain the wide variability in its phenotype observed across different cohorts.

Fig. 3 – Features of aniridia-associated keratopathy (AAK) observed using in vivo confocal microscopy. Relative to the healthy cornea (A, D, G), corneal homeostasis in aniridia is chronically perturbed. A: Normal healthy corneal epithelium with a clear cell mosaic. B: Epithelium with a conjunctival phenotype containing goblet cells (arrows) and inflammatory cells (bright reflective objects) and (C) epithelial cysts (arrows) thought to contain mucin. D: The limbal palisades of Vogt (arrows) within an intact epithelial cell mosaic (asterisk). E: Abnormal cellular structure and blood vessels (white arrows) with sprouting new vessels (asterisk) and inflammatory cells (black arrows). F: A fibrovascular pannus (asterisk) eventually replaces the limbal border with conjunctival epithelial cells (arrow). G: Normal subbasal nerve plexus containing high density of nerves. H: Sparse distribution of nerves (black arrow) and mature antigen-presenting dendritic cells (white arrows) in the central subbasal plexus. I: High density of dendritic cells. All images are from grade 2 AAK corneas with a transparent central cornea, and are 400 × 400 µm. Images courtesy of N. Lagali.

PAX6 is a highly conserved gene that plays an important role in embryonic development, particularly ocular development, and its haploinsufficiency leads to the abnormal development of eye structures and subsequent complications later in life. Heterozygous loss-of-function mutations in PAX6 typically reduce its protein abundance by 50%, which has an effect on multiple biological processes, including angiogenesis, cytoskeletal organization, cell adhesion, retinoic acid metabolism, and oxidative stress. Moreover, because PAX6 is expressed in multiple ocular structures, its dysregulation can disrupt the interplay between them. Based on clinical observations and animal experiments, the mechanisms underlying progressive AAK appear to be multifactorial and include the reduction of cell adhesion molecules as well as abnormal corneal healing, extracellular matrix metabolism, and corneal epithelial differentiation; however, the molecular mechanisms underlying each specific
pathophysiology are difficult to elucidate because PAX6 controls multiple signaling pathways, such as PI3K/AKT/mTOR and MAPK (MEK/ERK).^{91}

AAK is often associated with progressive LSCD because findings such as inflammation and conjunctivalization (opacification and neovascularization) causing pain and loss of vision are present in both conditions. LSCD is a disease caused by a loss of limbal epithelial stem cells (LESCs) due to physical or chemical trauma. There are various theories about the role of LESCs in AAK. Some have suggested PAX6 haploinsufficiency reduces the number of LESCs over time, but in one aggressive case of multiple PAX6 and ELP4 exon deletion, no reduction in the number of epithelial progenitor cells was detected.^{136} Therefore, others suggest that AAK is caused by abnormal LESC function, including proliferation and differentiation, rather than LESC deficiency.^{136,134} There is insufficient evidence, however, for abnormal migration and proliferative potential of LESCs in aniridia patients. An alternative theory is the mesenchymal transdifferentiation of LESCs, which is supported by the expression of conjunctival and epidermal differentiation markers (cytokeratin 13 and 10, respectively) and lack of expression of classic corneal epithelial markers (cytokeratin 3 and 12) in the corneal epithelium of AAK patients.^{255,95} In addition, AAK is characterized by the infiltration of goblet cells in severe cases.^{82} Together this suggests that corneal opacification might be caused by conjunctivalization, but it is unclear if it is caused by a loss of the corneal–conjunctival barrier or due to mesenchymal transdifferentiation.^{76,97}

The normal function of LESCs depends on the instructive nature of the niche microenvironment, as influenced by the ocular surface and neighboring structures, which gives another possible explanation for the symptoms present in AAK. Namely, the corneal nerves that would normally provide trophic support and homeostasis, are reduced by 50% in their density at birth in aniridia.^{44,84} Other abnormalities found in the AAK limbal niche are abnormal melanocytes that contain no melanosomes and melanin granules.^{139} As a result, pigmentation deficiency of limbal cells could enhance their sensitivity to oxidative stress and inflammation. In addition, alterations in the trabecular meshwork and Schlemm canal impact the outflow of aqueous humor, causing the ocular hypertension that develops in the majority (50–75%) of AAK patients.^{79} The dysfunction of the lacrimal and meibomian glands results in abnormal tear film osmolarity and protein composition. Elevated levels of pro-angiogenic and pro-inflammatory cytokines, including FGF2, IL-17A, IL-1β, IL-8, IL-9, IL-27, MIP-1α, and the reduced expression of angioregressive factors, including soluble VEGF receptor-1 (sFlt-1), were found in the tear film and pannus tissue of aniridia patients.^{2,73,87} Moreover, AAK is characterized by corneal infiltration of immune cells, including mature antigen-presenting dendritic cells and leukocytes.^{82} Collectively, this suggests that the ocular surface is chronically inflamed, which also contributes to an abnormal limbal niche microenvironment.

Still others have hypothesized that AAK progression is driven by gradual degradation of the limbal niche.^{90} This latter theory is supported by evidence of the loss of palisades of Vogt, the degradation of the basal membrane and Bowman layer leading to direct contact between basal cells and mesenchymal stromal cells, and abnormal extracellular matrix (ECM) composition.^{139} However, it is difficult to distinguish primary from secondary events in AAK progression.

Together these findings suggest an abnormal microenvironment and dysregulation of LESC function may lead to AAK progression. For the successful management of AAK, a detailed understanding of its pathogenesis is needed. Further studies are likely to reveal that multiple mechanisms are involved.

4. Management of AAK and potential future directions

Clinical management of AAK is challenging due to the multifaceted nature of the ocular surface pathology and the high risk of complications after interventions. The treatment approach is patient-specific, guided by the disease stage and the presence of other ocular complications, including cataract, glaucoma, and dry eye. While conventional treatment is geared towards symptomatic relief, restoring functional vision, and supporting and maintaining a healthy ocular surface, new treatment approaches can slow AAK progression and prevent vision loss. In this section, the various approaches and future directions for AAK management are reviewed, including surgical techniques and pharmacological approaches (Fig. 4). It is worth noting that the treatment of AAK usually involves a combination of approaches tailored to the individual patient.

4.1. Surgical approaches

4.1.1. Pannus removal

Eyes with advanced AAK often develop a pannus (conjunctival overgrowth into the cornea) of varying thickness, which can compromise transparency and refractive function. Pannus removal is typically performed to restore a smooth ocular surface and thereby improve vision. Afterwards, the denuded areas can be re-epithelialized by cells from the unaffected cornea and limbus if the limbal stem cells are still partially functional; however, surgical interventions in eyes with AAK are challenging because of the high risk of complications.^{116,119} This high-risk situation involves coexisting glaucoma, progressive inflammation, limbal stem cell dysfunction, and corneal neovascularization, often leading to chronic wound healing problems and cornea melting.^{79} Therefore, surgical interventions to improve vision are warranted in the current management of AAK.

The most common approach to improve wound healing and regeneration of the ocular surface after pannus removal is using an amniotic membrane patch to cover the denuded corneal surface.^{128,55} Amniotic membrane can be used alone or in combination with a corneal transplant and cell therapy to treat AAK.^{340,21,39} It is believed that the positive effect may be caused by the cytokines and growth factors present in the amniotic membrane or that it functions as a barrier that redirects conjunctival epithelization at the denuded area.^{82} The exact mechanism of action of the amniotic membrane remains unknown, however, and has a limited long-term effect.
In addition, autologous serum eye drops or neurotrophic eye drops can be used to supplement the wound healing effect of amniotic membrane.

4.1.2. Corneal transplantation
Given the immunocompromised status of the ocular surface, corneal transplantation in AAK-affected eyes is challenging because of the high risk of transplant rejection and failure. Nonetheless, corneal transplantation may be indicated for optical and tectonic reasons. To reduce the risk of rejection, lamellar surgery is generally preferable to penetrating keratoplasty since the endothelium in aniridia is unaffected. This can be done either as deep anterior lamellar keratoplasty, replacing the majority of the stroma down to Descemet membrane, or as anterior lamellar keratoplasty, replacing only a proportion of the anterior stroma and leaving the most posterior recipient stroma intact. In case of severe AAK with deep corneal stromal scarring and neovascularization, penetrating keratoplasty may be necessary, but it has poor success rates due to the high risk of graft rejection, wound healing problems, and neovascularization of the transplanted stroma. In addition to a lower risk of immune rejection, another advantage of anterior lamellar keratoplasty is the possibility to exchange the lamellar graft if later opacification of the transplanted corneal stroma occurs. Importantly, before keratoplasty, the eye should first undergo successful limbal stem cell transplantation (LSCT) to improve the prognosis for long-term success. Alternatively, keratolimbal allograft transplantation followed by subsequent corneal transplantation is used to treat AAK. It is thought that keratolimbal allograft restores the limbus and provides a supply of allogeneic LESC, which results in a stable ocular surface in 65.9% of the eyes after 7.9 years. Functional and quality-of-life improvements are modest, however, and the burden of multiple surgical procedures and lifelong immune suppression is considerable. A potential future improvement could be the combination of LSCT and deep anterior lamellar keratoplasty with angioregressive and antiangiogenic treatment.

4.1.3. Keratoprosthesis
When corneal transplantation is infeasible or has failed repeatedly, Boston type I keratoprosthesis (Kpro) may be considered as a last resort in severe AAK-affected eyes.
The benefit of the Boston type I Kpro is that the optical cylinder cannot opacify or become vascularized due to the artificial nature of the central portion. It has many side effects and potential complications, however, such as retroprosthetic membrane formation, corneal melting, and glaucoma. Recently, telemetric intraocular pressure sensors were implanted with Boston type I Kpro to measure intraocular pressure and help manage glaucoma.

In case of severe dryness of the keratinized ocular surface, osteo-odonto keratoprosthesis or Boston type II Kpro could be considered, but both require multiple invasive surgeries that increase the risk of developing aniridia-associated fibrotic responses and exacerbating glaucoma.

4.1.4. Cell therapy

Since AAK is associated with LSCD, generally treatments to replace abnormal LESCs to restore a healthy corneal epithelium have been applied. For unilateral LSCD, a range of autologous limbal stem cell therapies have been developed, including cultivated limbal epithelial transplantation, where a biopsy from the unaffected eye is cultivated ex vivo and transplanted onto the denuded affected eye. Bilateral insufficiency in patients with aniridia, however, prevents autologous cell transplantation and therefore requires other sources of LESCs for ocular surface reconstruction. Allogeneic and autologous cell sources, such as limbal cells, oral mucosal stem cells, differentiated human pluripotent stem cells, or mesenchymal stromal cells (MSCs) have therefore been considered to treat AAK.

Allogeneic cultivated limbal epithelial transplantation using cadaveric donor cells showed only short-term success in treating severe AAK-affected eyes, because of graft rejection in the long-term. Living related conjunctival-limbal allografts are more immune compatible and improve graft survival relative to corneal transplant, but compatible donors are not always available. Therefore, researchers have focused on other cell sources.

For example, more recently cultivated oral mucosal epithelial transplant using autologous oral mucosal epithelial cells obtained from a buccal mucosal biopsy that are cultured ex vivo prior to transplantation are used as cell source. Cultivated oral mucosa epithelial transplant showed visual improvement in LSCD and AAK cases in more than 50% of the eyes; however, long-term effects are unknown. Because oral mucosal cells do not normally express PAX6, it will be important to understand whether the mutated PAX6 gene in aniridia patients influences the differentiation into corneal epithelial cells. Additionally, oral mucosal epithelial cells are inherently different from corneal epithelial cells and therefore may require additional manipulation to possess the properties needed to improve vision.

Human PSCs, such as embryonic stem cells and induced pluripotent stem cells, provide novel opportunities for cell therapies, but guiding their differentiation into specific cell populations to establish a corneal epithelial transplant is complex. There are several established methods for differentiation of corneal epithelial cells and limbal stem cell (LSCs) from human pluripotent stem cells (hPSCs), including corneal cell-conditioned media, growth factors, inhibitors, and small molecule approaches. Recently, the first patients have been treated with induced pluripotent stem cell-derived corneal epithelial cells to treat LSCD and showed improved vision, but long-term efficacy and safety is not yet
Fig. 6 – Fine-needle diathermy (FND) applied to regress corneal neovascularization in a non-aniridia case. A: Preoperative eye with thick invading vessel (arrow). B, C: Two months and 15 months after FND combined with anti-VEGF therapy as a pretreatment to promote subsequent graft survival, the vessels (arrows) have almost completely regressed and transparency has been restored substantially. (Reprint from with permission).

4.1.5. Immuno suppression

Although the cornea is regarded as an immune-privileged tissue, graft failure frequently occurs. The current treatment approaches, some have proposed the construction of a human corneal surface by combining cells with scaffold. Currently a phase I/II clinical trial of a tissue engineered product which brings together LESCs and supporting stromal cells with type I collagen to treat patients with AAK is ongoing (NCT05044598). Despite decades of intensive research, we still lack an understanding of the regulatory conditions of the instructive nature of the niche microenvironment, which prevents us from harnessing the full therapeutic potential of cell-based therapies.

Another challenge is that current cell expansion methods for primary LESCs do not significantly increase their number in vitro. It is unclear whether enough LESCs can be transferred to the damaged ocular surface for long-term restoration of the stem cell population in AAK. Therefore, if stem cells can be better identified, isolated, and expanded/maintained in culture, stem cell-based graft quality may be improved with a more predictable clinical success. Markers including ABCB5, CD200 and ABCG2 that allow purification of the clinically-relevant cell population would significantly improve both the safety and efficacy of therapy.

Furthermore, immunosuppression protocols, human leukocyte antigens (HLA)-matching, and outcome measures vary between studies, making it difficult to assess treatment efficacy. Another significant problem when assessing clinical outcomes of stem cell transplantation to treat any form of LSCD, including AAK, is the lack of a universal and objective grading tool for assessing post-transplantation results. Additional limitations are the high risk of complications after interventions of AAK-affected eyes leading to poor survival of cell-based grafts. For long-term success, approaches to reduce or eliminate immunogenicity of cellular therapies are explored, such as genetically engineered HLA-type cell lines and shielding. Additionally, pharmacological approaches, including immunosuppression and anti(lymph)angiogenic treatments, can reduce the risk of transplantation failure. Poor long-term clinical results after LSCT suggest that new therapeutic strategies should be developed by addressing ocular immunity and supporting the limbal stem cell niche environment.

Overall, induced pluripotent stem cells also provide possibilities to transplant autologous cells for personalized treatment; however, the sourcing of autologous cells from aniridia patients for reprogramming is likely undesirable because of their underlying genetic defect. Additionally, such a personalized approach is likely to be costly and therefore other strategies to avoid immune responses are being developed.

Another example, MSCs, which possess unique immunomodulatory properties and can be sourced in large quantities, are an attractive novel source for cell therapy. For instance, they are clinically used to treat inflammatory diseases or suppress host rejection, and they possess differentiation potential, homing properties and trophic effects. Although it is difficult to differentiate them into corneal epithelial cells in vitro, nondifferentiated MSC showed therapeutic potential for ocular surface regeneration which was attributed to their trophic effect. While these data are encouraging, it remains to be seen if the (co-)application of MSCs could be a viable approach for treating AAK in the long term.

Despite decades of research, the therapeutic mechanism of LSCT remains unclear. Transplanted cells may exert their therapeutic effects via trophic support or immune modulation rather than through stem cell repopulation and differentiation. Questions therefore arise from LSCD studies if transplanted cells survive in the long term and actively contribute to epithelial maintenance, or if they have an indirect effect on the clinical outcome. In AAK, it is unknown how long transplanted allogeneic donor limbal cells survive in the host cornea and whether the underlying reasons for LSCT failure differ between acquired LSCD and AAK.

In addition, it is likely that the abnormal limbal niche observed in aniridia will preclude grafted stem cells from lodging in the limbal region. Without a functioning microenvironment, the transplanted cells lack adequate post transplantation support, and their function might only be transient. Therefore, reconstruction of a biomimetic limbal niche to support normal cell function is being pursued. For example, it has been shown that the biomechanical stiffness of the limbus affects the capacity of epithelial stem cells to regenerate the corneal epithelium. Using tissue engineering
of corneal graft rejection is based on steroids and other immune-modulating agents. Postoperative local immunosuppression is often achieved using topical steroids, such as prednisolone and dexamethasone. Additionally, systemic immune suppression, such as tacrolimus, azathioprine and mycophenolate mofetil is used to control inflammation and reduce the risk of early allograft rejection. Systemic and local immunosuppression have also been used in combination. In clinical practice, both local and systemic immunosuppression in corneal transplantation and LSCT have been applied with variable success. While the long-term use of immunosuppression post corneal transplantation is crucial for graft survival, the benefits in allogeneic cultivated limbal epithelial transplantation remain unclear as there are conflicting studies on the long-term survival of donor cells. Moreover, it is difficult to draw conclusions from studies with varying regimens. While these systemic and/or topical immunosuppression regimes are also applied in aniridia patients, the transplantation success rate remains low. For this reason, the development of more efficient protocols for immunosuppression specifically for aniridia patients post corneal transplantation or LSCT is imperative. Ideally, the regimen should be based on local approaches to avoid severe long-term side effects of systemic immunosuppression. Furthermore, the lack of evidence for allogeneic LESC survival beyond a relatively short period of time prompts ethical questions regarding the continuation of immunosuppression beyond 9 months, which is associated with significant side effects.

4.1.6. Regression of corneal vascularization

The avascular nature of the cornea is essential for maintaining transparency, although the mechanisms behind it are not fully understood. In advanced AAK significant corneal vascularization leads to opacity, but regression of surface or deeper vessels in these areas generally improve transparency. Furthermore, preoperative regression of blood vessels prior to corneal transplantation is necessary to prevent recurrent vascularization and bleeding into the interface. Such bleeding can cause a prolonged wound healing response and leads to significantly reduced vision. Photodynamic therapy has also been shown to regress blood and lymphatic vessels, including a significant percentage of the mature ones, promoting graft survival in a mouse model. Pharmacological suppression of corneal vessels alongside these approaches may further prolonged the angioregressive effect and could be considered.

4.2. Pharmacological approaches

The ocular surface of AAK patients is characterized by increased angiogenic signaling, suggesting an imbalance between pro- and antiangiogenic factors leading to pathological hem- and lymphangiogenesis. In AAK progression, inflammation and angiogenesis are associated and defined by the presence of inflammatory cells, corneal nerve deficit, limbal corneal thickening and corneal neovascularization with increasing AAK grade. Often vessels start to occupy the peripheral corneal regions before extensive damage of the epithelium takes place. Blood and lymphatic vessels facilitate inflammation and the release of cytokines by propagating antigens and immune cells to the ocular surface. Here we describe the pharmacological approaches that could modulate either inflammation, neovascularization, tear abnormalities or PAX6 protein levels.

4.2.1. Anti(lymph)angiogenic treatment

Antiangiogenic therapy could possibly reduce corneal neovascularization and angiogenesis in AAK progression. To achieve a corneal hem- and (lymph)angiogenic effect, it may
be beneficial to consider pharmacological suppression of corneal vessels with topical agents, such as anti-VEGF compounds. Bevacizumab, a monoclonal antibody specific to the VEGF-A ligand, is considered the first-line treatment for corneal neovascularization (used off-label), either topically or via subconjunctival injections.\textsuperscript{12,13} Notably, the use of bevacizumab in a young patient to treat AAK-related corneal neovascularization reduced the number of vessels and delayed AAK progression over several years.\textsuperscript{89}

Other anti-VEGF compounds, including ranibizumab, afibbercept, pegaptanib, and VEGF-receptor tyrosine kinase inhibitors demonstrated partial efficacy in treating corneal neovascularization, but are not yet approved for clinical application in the cornea and would also be considered as off-label use.\textsuperscript{100,13,17,28,36,49,66} Furthermore, the blockade of the insulin receptor substrate-1 (IRS-1) by GS-101 (Agnanisen) also inhibits VEGF activity and thereby corneal hem- and (lymph)angiogenesis in phase II and III clinical trials (NCT02947867).\textsuperscript{12,27,30} This broad antiangiogenic and anti-inflammatory approach has the benefit of avoiding the neurotoxic side effects of pure anti-VEGF therapy.\textsuperscript{98} Because partially inhibiting progressive corneal (lymph)angiogenesis using anti-VEGF compounds is shown to be safe and effective, more compounds are expected to receive approval for topical application in the cornea. This topical regimen can also be combined with local angioregression, like fine-needle diathermy and photodynamic therapy.

In addition to possibly hindering AAK progression, antiangiogenic agents could also be used to promote graft survival by regressing neovascularization. Anti-VEGF compounds are used to regress blood vessels after LSCT to treat LSCD.\textsuperscript{22} A recent study, however, demonstrated that it induced differentiation of putative LESCs in vitro and should be considered with caution in the context of LSCT.\textsuperscript{118} In the case of mature blood vessels observed in advanced AAK, the aforementioned agents may not be as effective in regressing established blood vessels prior to LSCT. For this reason, other approaches should be explored, such as photodynamic therapy and fine-needle diathermy. Because these physical methods are already used clinically to treat other ocular conditions, clinical practice of these modalities to treat AAK may be streamlined in the near future. Alternatively, UVA-based corneal collagen crosslinking is less aggressive and avoids the rebound VEGF upregulation after fine-needle diathermy.\textsuperscript{23,98} The effectiveness of these compounds and physical methods, alone or combined, in improving LSCT outcomes in aniridia remains to be explored preclinically and in clinical trials. Given the trophic influence of blood vessels on the limbal niche, it remains to be determined if a completely vessel-free limbal transplant region is conducive to long-term LESC survival. The trophic versus the immune function of blood vessels likely requires a careful balance for LESC survival.

4.2.2. Anti-inflammatory and tear film treatment

Lymph- and angiogenesis facilitate infiltration of inflammatory cells, including antigen-presenting dendritic cells and T-cells, that can lead to eventual rejection of foreign transplanted cells or tissue.\textsuperscript{147} The manipulation of dendritic cell and T-cell inhibitors has shown promise as a relatively new pharmaceutical strategy against transplant rejection. For example, coreceptor blocking agents such as CTLA4-Ig have been used to treat rheumatoid arthritis but also ocular inflammatory conditions in animal models.\textsuperscript{111,143,151,51,56} Moreover, B- and T-lymphocyte attenuator is used to suppress allogeneic kidney transplants rejection by regulating T-cell receptor downstream signals and inflammatory cytokine production.\textsuperscript{164,138} Because immune checkpoints are a critical component of the corneal immune privilege, immune checkpoint inhibitors could be used to attenuate transplant rejection, but research is on this topic is currently lacking.

Tear abnormalities in aniridia patients result in a pro-inflammatory environment that destabilizes the ocular surface.\textsuperscript{73,87} Optimizing the ocular surface using artificial tears with anti-inflammatory activity could be the first step in managing AAK. Autologous serum eye drops provide lubrication and contain various growth factors, vitamins, and immunoglobulins that support the proliferation, migration, and adhesion of corneal epithelial cells.\textsuperscript{92} Autologous serum eye drops were efficient in treating the inflammatory and angiogenic factors of LSCD and LSCT.\textsuperscript{108,160,8} Also in patients with mild to moderate AAK, autologous serum eye drops were beneficial in the short term.\textsuperscript{103} When autologous serum is unavailable, allogeneic serum eye drops can be considered. Alternatively, amniotic membrane-derived eye drops may provide an interesting alternative, because of their regenerative and nourishing properties;\textsuperscript{114} however, no commercial product is yet available, and more preclinical and clinical research is needed. For clinical research, it is critical to select patients carefully taking clinical genetics into consideration and identify early AAK onset, ideally at grade 1 or 2, for possible therapeutic intervention. Possible interventions would require careful and long-term monitoring owing to the slowly progressive nature of AAK. Nevertheless, early topical pharmacotherapy using amnion-derived or serum-derived approaches to prevent or delay AAK progression is an intriguing concept that warrants further study.

4.2.3. Modulation of PAX6 levels

Another approach to halt AAK progression is to increase PAX6 protein levels in the cornea to compensate for the nonfunctional mutant allele product. Direct approaches, using a recombinant PAX6 protein fused to a cell penetrating peptide, rescued phenotypic defects of PAX6\textsuperscript{134}cells in vitro.\textsuperscript{134} Clinical use, however, is limited by the safety and efficiency of delivering the compounds into cells. In addition, it is difficult to determine the appropriate dosage of directly-delivered PAX6 protein, as both too little or too much PAX6 could lead to undesirable effects. An alternative therapeutic approach is to target the nonmutant allele to overproduce the protein. This concept has been demonstrated by inhibiting the MAPK kinase (MEK) pathway by several small molecules. For example, application of MEK inhibitors ritanserin and duloxetine in human corneal limbal epithelial cells led to the upregulation of PAX6 and increased PAX6 production.\textsuperscript{122,25,40} Since duloxetine is already used to treat severe depression
and anxiety and relieve peripheral neuropathy, without apparent side effects, it could be easily translated to aniridia patients as soon as in vivo efficacy will be demonstrated. In addition, MEK inhibition by the experimental drug PD0325901 showed similar effects in a mouse model of aniridia, partially reversing the AAK phenotype; however, caution of their use on aniridia patients must be considered, as MEK inhibitors have cardiac and ophthalmologic side effects when taken systemically. Another drug, ataluren, is a nonsense mutation suppressor targeting only the mutant allele. Ataluren showed elevated Pax6 protein levels in vitro and in an aniridia mouse model, putatively rescuing the AAK phenotype. A Phase II clinical trial was performed in patients with aniridia, in which ataluren was given orally with short follow-up; however, there was no statistical difference in the chosen endpoint of reading speed (NCT02647559). Furthermore, the potential efficacy is limited only to those patients with premature stop codon mutations, comprising about 70% of cases of congenital aniridia. Similar in vitro data have been reported with another nonsense suppression drug (gentamicin G418).  

4.2.4. Gene therapy  
Gene therapy is a powerful strategy aimed at correcting disease-causing genetic alterations. Some gene therapies are already approved and used in ophthalmology, including Luxturna to treat inherited retinal dystrophy. Genetic modulation aiming to increase expression of the haploinsufficient PAX6 gene expression is increased holds great promise to restore the physiological Pax6 protein level. Four gene therapy approaches could possibly target genetic alterations to treat aniridia: gene augmentation, gene enhancing, gene silencing or protection, and gene editing.  

Gene augmentation is the delivery of a functional copy of the gene to correct for a defective copy. Many clinical trials are underway to restore the expression of a mutant gene in retinal disorders. Gene enhancing modulates the activity of regulatory elements, such as promoters, enhancers, silencers, and insulators, to upregulate the expression of the existing normal gene copy. It has been shown that DNA regulatory elements can drive Pax6 expression using transcription activators or small promoters, which could be a promising approach to increase the Pax6 protein level. Gene silencers are small noncoding RNAs, such as small interfering RNA, antisense oligonucleotides, or micro-RNA, that inhibit the translation of mRNA. Gene silencing could be used to target Pax6 inhibitors to increase its expression. Furthermore, gene protectors, such as RNA decoys, could regulate RNA interference. For example, decoy gene therapy has shown to suppress Pax6-specific micro-RNA and increased Pax6 protein production in an aniridia mouse model. Gene editing corrects the defective gene through, for example, a CRISPR/Cas9-based gene editing strategy to precisely target and correct Pax6 mutations through inactivation of the mutated base in the short-guide RNA sequence. CRISPR/Cas9-based gene editing can be used to treat dominantly inherited conditions permanently and has been used in preclinical animal models to modify mutations involved in ophthalmic diseases. Recently, this strategy has been used to correct a Pax6 mutation in an aniridia mouse model. Given the diversity reported in the PAX6 mutations involved in aniridia, it is likely that a personalized approach will be needed for some patients. Although these gene therapy approaches have yielded promising results in various models of aniridia, they have to date not been translated into clinical trials.  

Several techniques are available to deliver nucleic acids into the cells of the ocular surface, including viral vectors like adeno-associated virus, adenovirus and lentivirus for transduction, or liposomes, nanoparticles, and in vivo electroporation for transfection. The adeno-associated virus-based system has been tested in several experimental models of human ocular diseases with encouraging results. Furthermore, because the cornea is easily accessible for local therapy, long-lasting treatment is possible using eye drops or contact lenses for topical delivery. In addition, neighboring ocular tissues, including the sclera, stroma, or ciliary muscle, could serve as a “bio-factory” for long term expression and secretion of therapeutic proteins after injection of reporter gene-encoding plasmids.  

There are still several challenges to overcome for these approaches to be a success, especially dosing, toxicity, immune response, and off-target effects. The complex expression patterns during ocular development and the tissue-specific dosage of the PAX6 transcription factor make it challenging to develop gene therapies for aniridia. Moreover, the overexpression of Pax6 leads to corneal abnormalities. Therefore, dosing will be crucial to reach a physiological expression level. To address issues of safety and specificity, tools to control transgene expression and control tissue-specific expression, such as by tissue-specific and inducible promoters, need to be considered.  

5. Conclusion  
Having explored the fundamental basis of AAK pathogenesis, we can appreciate the complexity of the disease that involves multiple mechanisms. For a detailed understanding of the disease mechanism at the molecular, cellular and developmental levels, much work remains to be done. Since AAK progression is often the most sight-limiting factor in congenital aniridia, an effective treatment would greatly enhance the quality of life. For the management of AAK, onset and progression should be classified by careful slit lamp examination of the cornea using a grading scheme. Advanced examination techniques, including in vivo confocal microscopy and optical coherence tomography, allow detection of additional abnormalities. Because AAK is characterized by high genetic and phenotypic variability, its management must be tailored for each individual case. To halt AAK progression, the focus should be on treating ocular surface inflammation, vascularization and the poor (neuro)trophic environment. Because the prognosis for vision recovery after any surgical intervention in aniridia is generally poor, whether or not to perform surgery and the type of intervention should be carefully considered including preoperative and postoperative care. Systemic and topical immunosuppression and anti lymph- and angiogenic treatment should always be considered in corneal transplantation or LSCT. Novel pharmacological approaches including eye drops,
immunomodulation, gene therapy and regulation of PAX6 levels are being developed. However, conducting clinical trials in a rare and heterogeneous disease such as aniridia is a challenge. Nonetheless, preclinical research using cellular and AAK animal models has demonstrated the possibility of novel therapeutics that could possibly delay or prevent the onset or progression of AAK in the future. Therefore, further efforts must be made to evaluate promising therapeutic alternatives, to eventually bring the best candidates into human clinical studies.

6. Disclosures

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Maria Notara reports travel was provided by COST. Maria Notara reports a relationship with University Hospital Cologne Centre of Ophthalmology that includes: employment. Neil Lagali reports article publishing charges and travel were provided by European Cooperation in Science and Technology. Member of the Scientific Committee of Aniridia Europe, a patient organization. Chair of the EU Cooperation on Science and Technology Action ANIRIDIA-NET.

Funding

This work was supported by the European Union’s Cooperation on Science and Technology (COST) Program, under COST Action CA-18116 ANIRIDIA-NET. Aniridia: networking to address an unmet medical, scientific, and societal challenge; DFG German Research Council FOR 2240 (www.for2240.de) to C. C. and M. N.; the European Joint Programme on Rare Diseases (EJP RD 2020) to N. L., D. B. G., D. A. (AAK-INSIGHT); the Science Foundation Ireland Investigator Award (Grant 12/IA/1624), the European Regional Development Fund and the European Union’s Horizon 2020 Research and Innovation Programme (Grant 814439) to T. R.; Academy of Finland (Grant 338988) to H. S.; the Dutch Research Council ZonMw TOP (Grant 91217058, VISION) to M. M. D., S. F. and V. L. S. L.

CRediT authorship contribution statement


Declaration of Competing Interest

The authors have no conflicts of interest to declare.

Acknowledgments

We would like to acknowledge the illustrators Daniela Velasco for the illustrations in Figs. 1 and 4 and Sara T. Nøland for the illustrations in Fig. 2. We cordially thank Aniridia Europe for support and motivation.

Method of Literature Search

In this perspective review, we consulted with experts in the field and formulated our understanding of AAK pathogenesis and future perspectives on AAK management.

REFERENCES


14

ARTICLE IN PRESS

SURVEY OF OPHTHALMOLOGY XXX (XXXX) XXX–XXX


